United Therapeutics said its second Phase 3 trial of Tyvaso (treprostinil) for idiopathic pulmonary fibrosis met endpoints, strengthening the company’s case for a supplemental NDA and potential priority review. The program builds on similarly strong results from the first Phase 3 trial reported last year. In the second study, Tyvaso showed superiority over placebo in change in absolute forced vital capacity and reduced the risk of clinical worsening. United also reported that the safety profile remained well tolerated. The company’s strategy would position Tyvaso for a major commercial launch in 2027, contingent on regulatory review timelines. The dual Phase 3 success improves the evidence base for regulators deciding on expansion of use within IPF. For the pulmonary market, the update raises competitive stakes around inhaled prostacyclin pathway therapies as companies seek to capture differentiated label opportunities based on clinical endpoint performance.